Solid MRI contrast agents for long-term, quantitative in vivo oxygen sensing
Name
Liu-2014-Solid MRI contrast a.pdf
Size
1.06 MB
Format
Adobe PDF
Checksum (MD5)
4b346b0f586f0ff3e54dfca28fa58798
Author(s)
Liu, Vincent Hok
Vassiliou, Vassiliou, Christophoros C.
Imaad, Syed M.
Cima, Michael J.
Vassiliou, Christophoros C.
Date Issued
April 2014
Journal
Proceedings of the National Academy of Sciences of the United States of America
Publisher
National Academy of Sciences (U.S.)
Citation
Liu, V. H., C. C. Vassiliou, S. M. Imaad, and M. J. Cima. “Solid MRI Contrast Agents for Long-Term, Quantitative in Vivo Oxygen Sensing.” Proceedings of the National Academy of Sciences 111, no. 18 (April 21, 2014): 6588–6593. © National Academy of Sciences
Version
Final published version
Abstract
Targeted MRI contrast agents have proven useful in research and clinical studies for highlighting specific metabolites and biomarkers [Davies GL, et al. (2013) Chem Commun (Camb) 49(84):9704–9721] but their applicability in serial imaging is limited owing to a changing concentration postinjection. Solid enclosures have previously been used to keep the local concentration of contrast agent constant, but the need to surgically implant these devices limits their use [Daniel K, et al. (2009) Biosens Bioelectron 24(11):3252–3257]. This paper describes a novel class of contrast agent that comprises a responsive material for contrast generation and an injectable polymeric matrix for structural support. Using this principle, we have designed a contrast agent sensitive to oxygen, which is composed of dodecamethylpentasiloxane as the responsive material and polydimethylsiloxane as the matrix material. A rodent inspired-gas model demonstrated that these materials are functionally stable in vivo for at least 1 mo, which represents an order of magnitude improvement over an injection of liquid siloxane [Kodibagkar VD, et al. (2006) Magn Reson Med 55(4):743–748]. We also observed minimal adverse tissue reactions or migration of contrast agents from the initial injection site. This class of contrast agents, thus, represented a new and complementary method to monitor chronic diseases by MRI.
MIT Department
Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science
Massachusetts Institute of Technology. Department of Materials Science and Engineering
Massachusetts Institute of Technology. Lemelson-MIT Awards Program
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1073/pnas.1400015111
